Conflicts of interest
MH, J.B.
EDWARDS
U.B. and J.B. represent the study heads of the DIGIT-HF-study and applied for funding of DIGIT-HF described above. U.B., J.B., A.K. H. v. d. L., C. V., M. B. and S.S. are members of the DIGIT-HF trial steering committee. U.B. received travel support and honoraria for lectures/consulting from Alnylam Pharmaceutical, Amgen, Astra Zeneca, Bayer Vital, Novartis, and Pfizer and institutional research support from Alnylam Pharmaceuticals, all not related to the current manuscript. J.B. has received honoraria for lectures/consulting from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cardior, Corvia, CVRx, Novartis, Pfizer, Vifor and institutional research support from Zoll, CVRx, Abiomed, all not related to the current manuscript. MB is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, ReCor, Servier and Vifor during the conduct of the study. A.J.R. received honoraria for lectures from AstraZeneca and Bayer, and travel support from Johnson&Johnson and Servier, all not related to the current manuscript. C.V. received honoraria for lectures/consulting from Abbott, Bayer, Biotronik, BMS, Boehringer Ingelheim, CVRx and Medtronic, all not related to the current manuscript. H.v.L is serving as medical director of Orgenesis, Inc, unrelated to the current manuscript. L.S.M. has no conflicts of interest with respect to the drug studied in this trial. MH received speakerhonoraria, grants and advisory honoraria form Roche Diagnostics, Boehringer Ingelheim, Astra Zeneca, Novartis, Vifor, Biopeutics, Sandoz, Baxter. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.